Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC

NCT03752723 is registered in ClinicalTrials.gov with Genexine, Inc. as lead sponsor.

NCT NCT03752723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03752723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC
Lead sponsor
Genexine, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 27, 2019
Completion date
May 11, 2023
Enrollment
84 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer